Points to Consider: Early Access to Experimental Products Programs

  • Recommend
  • Tweet
  • Print
  • Email

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Read the document (183 KB PDF)

Hide Date: 
Hide Date
Hide Add This: